Licensed Product Royalties. Subject to the terms of this Section 5.3 (and subject further to Section 5.6), Celgene shall pay Prothena royalties on Annual Net Sales, on a Licensed Product-by-Licensed Product basis during the applicable Royalty Term, equal to the following portions of Annual Net Sales of the applicable Licensed Product multiplied by the applicable royalty rate set forth below for such portion of Annual Net Sales during the applicable Royalty Term for each such Licensed Product, which royalties shall be paid in accordance with Section 5.3.7 (the “Per Licensed Product Annual Net Sales”). For clarity, the royalties (and royalty tiers) shall be calculated separately on a Licensed Product-by-Licensed Product basis. [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Per Licensed Product Annual Net Sales for a Given Licensed Product in a Given Calendar Year Royalty Rate Portion of Per Licensed Product Annual Net Sales of a given Licensed Product in a given Calendar Year above [***] [***]% Portion of Per Licensed Product Annual Net Sales of a given Licensed Product in a given Calendar Year above [***] [***]% Portion of Per Licensed Product Annual Net Sales of a given Licensed Product in a given Calendar Year above [***] [***]% Portion of Per Licensed Product Annual Net Sales of a given Licensed Product in a given Calendar Year above [***] [***]% Portion of Per Licensed Product Annual Net Sales of a given Licensed Product in a given Calendar Year above [***] [***]% Portion of Per Licensed Product Annual Net Sales of a given Licensed Product in a given Calendar Year above [***] [***]% Portion of Per Licensed Product Annual Net Sales of a given Licensed Product in a given Calendar Year above [***] [***]% Portion of Per Licensed Product Annual Net Sales of a given Licensed Product in a given Calendar Year above [***] [***]% Portion of Per Licensed Product Annual Net Sales of a given Licensed Product in a given Calendar Year above [***] [***]% Portion of Per Licensed Product Annual Net Sales of a given Licensed Product in a given Calendar Year above [***] [***]% The applicable royalty rate set forth in the table above will apply only to that portion of the Per Licensed Product Annual Net Sales of a given Licensed Product during a given Calendar Year that falls within the indicated range. For clarity, (i) if no royalty is payable ...
Licensed Product Royalties. In consideration for the licenses granted to Wyeth under Section 2.1 hereof, and in addition to those payments required to be made by Wyeth pursuant to Section 5.1, Section 5.2 and Section 5.3, Wyeth shall pay to Trubion royalties during the Royalty Period as set forth in Sections 5.4.2, 5.4.3 and 5.4.4 below, subject to the adjustments provided in Section 5.4.6 below.
Licensed Product Royalties. Calithera shall pay to HPP royalties on Net Sales of Licensed Products in the Territory as follows: Calendar Year Net Sales of Licensed Products Royalty Rate Less than or equal to $[***] [***]% Greater than $[***] and less than or equal to $[***] [***]% Greater than $[***] and less than or equal to $[***] [***]% Greater than $[***] [***]%
Licensed Product Royalties. Licensee will purchase all re-sellable Licensed Products from SLC, or SLC’s authorized affiliate. Licensee shall pay for all such Licensed Products on a cost plus twenty-five percent (25%) markup basis, unless otherwise agreed (the “Licensed Product Royalties”). For the avoidance of doubt, this Agreement does not grant Licensee the right to produce, manufacture or have manufactured Licensed Products for resale and any such production of Licensed Products shall constitute an infringement of SLC’s and/or Owner’s intellectual property rights.
Licensed Product Royalties. 7.6.1. ROCHE shall pay to SYNTA royalties on the aggregate worldwide annual (on a calendar year basis) Net Sales of each Licensed Product in the Territory, on a Licensed Product-by-Licensed Product basis, as follows: Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Aggregate Worldwide Annual Net Sales of Licensed Product Royalty Rate
Licensed Product Royalties. (a) Net Sales by Otsuka and Affiliates. Otsuka shall pay to MethylGene royalties on Calendar Year Net Sales in the Territory as follows on a Licensed Product by Licensed Product basis: Calendar Year Net Sales of the Licensed Product by Otsuka, its Affiliates and Sublicensees Royalty Rate Less than or equal to […***…] […***…] Greater than […***…] and less than or equal to […***…] […***…] Greater than […***…] and less than or equal to […***…] […***…] Greater than […***…] […***…] Royalties under this Section 6.6(a) on Net Sales of a Licensed Product in the Territory in a Calendar Year shall be paid at the rate applicable to the portion of Net Sales within each of the Net Sales levels during such Calendar Year. For example, if, during a Calendar Year, worldwide Net Sales of a Licensed Product were equal to $[…***…], then the royalties payable by Otsuka would be calculated by adding (i) the royalties with respect to the first $[…***…] at the first-level percentage of […***…], and (ii) the royalties with respect to the next $50,000,000 at the second-level percentage of […***…], for a total royalty of […***…]. For purposes of this Section 6.6(a) all Licensed Products containing the same Selected Compound shall be deemed to be the same Licensed Product.
Licensed Product Royalties. GSK shall pay EPIZYME incremental royalties on worldwide Annual Net Sales, on a Licensed Product-by-Licensed Product basis, at the royalty rates set forth in the table below: Worldwide Annual Net Sales Incremental Royalty Rates Portion up to but not including $[**] [** ]% Portion equal to or greater than $[**] up to but not including $[**] [** ]% Portion equal to or greater than $[**] [** ]% For example, if worldwide Annual Net Sales of a Licensed Product were $[**], the royalties payable with respect to such Annual Net Sales, subject to adjustment as set forth in this Section 6.8 below, would be [**]. Notwithstanding the foregoing, with respect to Licensed Products containing Licensed Compounds that are first identified by screening a GSK compound library at any time during the Research Term (provided that the Parties have mutually agreed to conduct such screening), the foregoing royalty rates shall be reduced to [**] percent ([**]%) of the otherwise applicable royalty rates.
Licensed Product Royalties. AZ shall pay to ABX the following royalties based on the annual Net Sales of each Licensed Product sold by AZ and its Affiliates during the Royalty Term for such Licensed Product. The royalty rates shall be determined on a Product-by-Product basis as follows: Annual Net Sales Non-Proprietary ABX Antigen Proprietary ABX Antigen For that portion of aggregate Net Sales that is less than U.S.$[Confidential treatment requested] [Confidential treatment requested] [Confidential treatment requested] For that portion of aggregate Net Sales that equals or exceeds U.S.$[Confidential treatment requested] but is less than U.S.$[Confidential treatment requested] [Confidential treatment requested] [Confidential treatment requested] For that portion of aggregate Net Sales that equals or exceeds U.S.$[Confidential treatment requested] but is less than U.S.$[Confidential treatment requested] [Confidential treatment requested] [Confidential treatment requested] For that portion of aggregate Net Sales that equals or exceeds U.S.$[Confidential treatment requested] [Confidential treatment requested] [Confidential treatment requested] For purposes of this Section 9.3.2, a Non-Proprietary ABX Antigen shall be any Collaboration Antigen other than a Proprietary ABX Antigen. For the avoidance of doubt, if ABX does not designate an Antigen as a Proprietary ABX Antigen pursuant to Section 4.17.2 before such Antigen is designated as a Proposed Antigen, such Antigen shall be a Non-Proprietary ABX Antigen. Further, the determination as to whether a Proprietary ABX Antigen remains a Proprietary ABX Antigen shall, with respect to any royalty payment, be made at the time such royalty payment obligation arises. The calculation of royalties under this Section 9.3.2 shall be conducted separately for each Licensed Product. Thus, if AZ sells more than one Licensed Product, the thresholds and ceilings in this Section 9.3.2 shall apply separately to each Licensed Product.
Licensed Product Royalties. During the applicable Royalty Term with respect to each Licensed Product, NexMed shall pay Allergan a royalty of twenty percent (20%) on Net Sales of such Licensed Product in the Territory.
Licensed Product Royalties. During the applicable Royalty Term, ICONIC shall furnish to Zymeworks a written report for each Calendar Quarter showing the Net Sales of Licensed Products sold by ICONIC and its Related Parties during the reporting Calendar Quarter and the Licensed Product Royalties payable under this Agreement in sufficient detail to allow Zymeworks to verify the amount of Licensed Product Royalties paid by ICONIC with respect to such Calendar Quarter, including, (i) on a country-by-country basis (and field-by-field basis in the event Zymeworks has exercised its Co-Promotion Option in such field(s)), the total gross amount invoiced for Licensed Products sold, the Net Sales of Licensed Products and the Licensed Product Royalties (in USD) payable, and (ii) the manner and basis for any currency 160 Competitive Information – Discovery Information. 161 Competitive Information – Financial Provisions and Other Commercially Sensitive Terms. 162 Competitive Information – Discovery Information. 163 Competitive Information – Financial Provisions and Other Commercially Sensitive Terms. 164 Competitive Information – Discovery Information. 165 Competitive Information – Financial Provisions and Other Commercially Sensitive Terms. 166 Competitive Information – Discovery Information. 167 Competitive Information – Financial Provisions and Other Commercially Sensitive Terms. 168 Competitive Information – Other Commercially Sensitive Terms. 169 Competitive Information – Other Commercially Sensitive Terms. 170 Competitive Information – Other Commercially Sensitive Terms. conversion in accordance with Section 5.2. Reports shall be due no later than […***…]171 following the end of each Calendar Quarter. Licensed Product Royalties shown to have accrued by each report provided under this Section 5.1.3 shall be due and payable on the date such report is due.
